BioSpace News Archive

We have seen the first encouraging results from the ongoing tasquinimod trial in multiple myeloma and started a new combination study with naptumomab and docetaxel in lung cancer

Innovent Biologics, Inc. announced that the National Medical Products Administration of China has accepted the supplemental New Drug Application for sintilimab in combination with chemotherapy for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma.

AlzeCure Pharma AB, a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, announced that the company is participating at Redeye Life Science Day 2021 on November 11 at 14:30 CEST, where CEO Martin Jönsson will present the company’s latest developments.

Talaris Therapeutics, Inc., a late-clinical stage cell therapy company, provided the first clinical update on its Phase 3 FREEDOM-1 study in living donor kidney transplant recipients, and also separately presented a clinical update and additional data from ongoing follow-up of its fully-enrolled Phase 2 study in LDKT recipients at the 2021 American Society of Nephrology meeting.

The Menarini Group announced that the U.S. Food and Drug Administration granted orphan drug designation to SEL24/MEN1703 for the treatment of Acute Myeloid Leukemia.

Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced the appointment of Jill Howe to its board of directors effective November 3, 2021.

Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced that it has expanded its partnership with Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases.

Santhera Pharmaceuticals announces the appointment of Stephanie Brown as President North America and a member of Santhera’s Executive Management team, effective December 1, 2021.

UNION therapeutics A/S, a privately-held, multi-asset, clinical stage, pharmaceutical company focused on immunology and infectious diseases, announced that the US Food and Drug Administration has granted Fast Track designation to oral orismilast for the treatment of moderate to severe AD.

Elekta invites analysts and investors to a presentation of the second quarter 2021/22 at 10:00 a.m. CET on November 25.